09 junio 2009
Children's Oncology Group y el National Cancer de EEUU Verifican la Fase II del Yondelis Pediatrico en 81 Hospitales .
P.D. Una Apuesta clara por parte de los Organismos Oncologicos de los Estados Unidos y Canada bajo la Supervisión de Johnson And Johnson ... y lojicamente Pharma Mar aportando el Farmaco .
Yondelis in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors .
This study is currently recruiting participants.
Verified by National Cancer Institute (NCI), June 2009
First Received: October 3, 2003 Last Updated: June 6, 2009 History of Changes
Sponsors and Collaborators: Children's Oncology Group
National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00070109
Show 81 Study Locations
Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Investigators
Study Chair: Sylvain Baruchel, MD The Hospital for Sick Children
More Information
Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database
No publications provided
Responsible Party: Children's Oncology Group - Group Chair Office ( Gregory H. Reaman )
Study ID Numbers: CDR0000329999, COG-ADVL0221
Study First Received: October 3, 2003
Last Updated: June 6, 2009
ClinicalTrials.gov Identifier: NCT00070109 History of Changes
Health Authority: Unspecified